Ir para o conteúdo principal

Context Therapeutics (NASDAQ: CNTX) — Perfil da empresa, notícias e dados financeiros

Logo de Context Therapeutics
CNTX Context Therapeutics
Context Therapeutics primary media
Perfil da empresa

Context Therapeutics

Context Therapeutics (NASDAQ:CNTX) is a biotechnology company focused on advancing treatments for hormone-driven cancers, with a deep commitment to innovation in this critical area of oncology. The company's operations center around developing small molecules and biologics that could potentially transform the therapeutic landscape for patients suffering from breast, ovarian, and other types of hormone-receptor-positive cancers. Among its leading projects is the development of novel therapies that aim to disrupt the cancer growth pathways, providing more effective and less toxic treatment options. The overarching objective of Context Therapeutics is to deliver breakthrough treatments that can significantly improve patient outcomes and quality of life, demonstrating their commitment to addressing the unmet needs in cancer care.

Resumo

Public USParticipação acionária
2015Ano de fundação
5Funcionários
Philadelphia, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
Philadelphia, US

Produtos e/ou serviços de Context Therapeutics

  • Onapristone extended release tablets, designed to block the progesterone receptor for treating progesterone-driven cancers.
  • Collaborations in clinical trials, combining their leading drug with other therapies for enhanced cancer treatment.
  • Development of novel therapies targeting hormone-driven cancers, aiming to provide new options for patients.
  • Research into the biology of progesterone receptor (PR) in cancer, supporting the foundation of their therapeutic development.
  • Preclinical programs focused on discovering additional candidates that target hormone receptors to expand their pipeline.
  • Partnerships with academic and research institutions to leverage cutting-edge science in hormone-driven cancers.

equipe executiva do Context Therapeutics

  • Martin A. LehrCo-Founder, President, CEO & Director
  • Jennifer Minai-AzaryCFO & Treasurer
  • Alex C. LevitChief Legal Officer & Corporate Secretary
  • Christopher BeckSenior Vice President of Operations
  • Jeffrey LiebmanAssociate Director of Accounting
  • Jennifer DashnauSenior Vice President of Technical Operations
  • Karen ChaginChief Medical Officer

Principais indicadores financeiros

Resultados divulgados pela Context Therapeutics, em USD.

Cap. de mercado
19,4 mi
Receita (TTM)
0
P/L
—
LPA (diluído, TTM)
-0.4
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Context Therapeutics
Fim do ano fiscalReceitaResultado operacionalLucro líquido
0-39,7 mi-36,1 mi
0-29,9 mi-26,7 mi
0-25,1 mi-24 mi
0-15,4 mi-14,8 mi